Market Reviews

Based on their commentary in the fourth quarter of 2021, orthopedic executives expect market disruption to persist through 2022.

The orthopedic market finds itself in familiar territory in early 2022, with record COVID cases impacting elective surgery volumes.

The orthopedic market outperformed expectations in the first half of 2021, given gaps in vaccine coverage and the surging delta variant.

As we near 2Q earnings, we're watching for a barometer of the market's recovery, momentum in M&A as well as the evolution toward digital.

The first quarter of 2021 began amid COVID's deadliest surge. However, encouraging signs point toward a second half recovery.

We estimate the orthopedic market declined in the low single digits for 4Q20 and in the low double-digits for the full year 2020.

Trauma players Acumed, Amplitude Surgical and Paragon 28 are likely to be positively impacted by Stryker's purchase of Wright Medical.

The fourth quarter of 2020 brought a dramatic surge in the pandemic that further depressed orthopedic surgical volumes worldwide.

The orthopedic industry faced unique challenges and profound uncertainty in 2020. We recap market's recovery through nine months and our 2020 projections.

A look into three companies outside the U.S. in the $100 million to $300 million revenue bracket: LimaCorporate, Medartis and AK Medical.